BBOT

1.8102.69%
NK

Neil Kumar

Co-Founder, CEO & Director

Dr. Neil Kumar, Ph.D., is Executive Chairman of BridgeBio Oncology Therapeutics, Inc. from April 20, 2026. He serves as an Independent Director at Maze Therapeutics, Inc. since March 27, 2026. He has been Director of LianMedical (formerly known as LianBio) since October 2019 and as executive chair of the board of managers of GondolaBio, LLC since August 2024. He serves as Member of Scientific Advisory Board of Driver Bioengineering, Inc. He is a Co-Founder of BridgeBio Pharma, Inc. and serves as its Chief Executive Officer and Director since April 2015. He served as President of BridgeBio Pharma, Inc. until July 23, 2024. He serves as Director of Phoenix Tissue Repair, Inc. He is Director of TheRas, Inc since August 2016. He serves as the Chief Executive Officer at Eidos Therapeutics Inc. and served as its Director since March 2016 until January 26, 2021. Dr. Kumar served as a Principal at Third Rock Ventures, LLC from 2011 to 2014. He joined Third Rock Ventures in 2011 and supported and managed various portfolio companies and focused on new company formation and due diligence. Dr. Kumar served as an Interim Head of Business Development and Operations at MyoKardia, Inc. and was its Interim Vice President of Business Development from 2012 to 2014. He served as an Associate Principal at McKinsey & Company from 2007 to 2011, where he developed strategies for pharmaceutical and medical device companies and helped lead McKinsey’s Personalized Medicine efforts. He was involved in the formation of a gene chip startup. Dr. Kumar was a Technical Consultant for AstraZeneca’s pathway signaling group. He is the author of several peer-reviewed papers in the fields of oncology and systems biology. He holds B.S. and M.S. degrees in Chemical Engineering from Stanford University and received his Ph.D. in chemical engineering from the Massachusetts Institute of Technology.

Positions